Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 0 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Penpulimab AI simulator
(@Penpulimab_simulator)
Hub AI
Penpulimab AI simulator
(@Penpulimab_simulator)
Penpulimab
Penpulimab is a humanized monoclonal antibody used for the treatment of cancer. It targets the programmed cell death protein 1 (PD-1) receptor.
Penpulimab was approved for medical use in China in August 2021, and in the United States in April 2025.
In the United States, penpulimab is indicated for the treatment of non-keratinizing nasopharyngeal carcinoma.
In August 2021, penpulimab received its first approval in China for the treatment of adults with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy.
In January 2023, the National Medical Products Administration of China approved penpulimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
The most common adverse effects associated with penpulimab include:
Penpulimab binds to the PD-1 receptor on T cells, preventing interaction with its ligands, PD-L1 and PD-L2. This blockade restores T-cell-mediated immune responses against tumor cells. The antibody has been engineered with modifications to its Fc region to eliminate Fcγ receptor binding and Fc-mediated effector functions, reducing the risk of immune-related adverse effects such as antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis.
Penpulimab demonstrates a slower dissociation rate from the PD-1 receptor compared to other PD-1 inhibitors, resulting in higher receptor occupancy and enhanced T-cell activity. This property is attributed to its unique binding interactions with the glycosylated N58 residue on the BC loop of the PD-1 receptor.
Penpulimab
Penpulimab is a humanized monoclonal antibody used for the treatment of cancer. It targets the programmed cell death protein 1 (PD-1) receptor.
Penpulimab was approved for medical use in China in August 2021, and in the United States in April 2025.
In the United States, penpulimab is indicated for the treatment of non-keratinizing nasopharyngeal carcinoma.
In August 2021, penpulimab received its first approval in China for the treatment of adults with relapsed or refractory classic Hodgkin lymphoma who have undergone at least second-line chemotherapy.
In January 2023, the National Medical Products Administration of China approved penpulimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer.
The most common adverse effects associated with penpulimab include:
Penpulimab binds to the PD-1 receptor on T cells, preventing interaction with its ligands, PD-L1 and PD-L2. This blockade restores T-cell-mediated immune responses against tumor cells. The antibody has been engineered with modifications to its Fc region to eliminate Fcγ receptor binding and Fc-mediated effector functions, reducing the risk of immune-related adverse effects such as antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis.
Penpulimab demonstrates a slower dissociation rate from the PD-1 receptor compared to other PD-1 inhibitors, resulting in higher receptor occupancy and enhanced T-cell activity. This property is attributed to its unique binding interactions with the glycosylated N58 residue on the BC loop of the PD-1 receptor.